What’s Next? Five Things To Look Out For In February
Humira Biosimilars Set To Launch In Canada
In the month ahead, Amarin is likely to reveal the latest on its plans to petition the US Supreme Court over generic versions of Vascepa, while biosimilar competition to Humira is set to arrive and the bulk of fourth-quarter and year-end financial results will emerge.
You may also be interested in...
Sandoz has confirmed the launch of its Hyrimoz biosimilar rival to Humira in Canada, with other biosimilars firms having also set their sights on a mid-February launch.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Despite the turbulence of 2020 and the pressures of the coronavirus pandemic, Sandoz has reported steady sales for the year, as biopharmaceuticals sales up by a fifth offset a slide in turnover from retail generics.